EIK1001 Dose Selected for Registrational Phase 2/3 Melanoma Trial

A dose of 0.60 mg/m² has been selected for EIK1001 in the randomized portion of the TeLuRide-006 trial (NCT06697301).¹

TeLuRide-006/KEYNOTE-G04 is a global, multicenter, randomized, double-blind, adaptive phase 2/3 registrational trial evaluating EIK1001 or placebo in combination with pembrolizumab (Keytruda) as first-line therapy for patients with advanced cutaneous melanoma. The dose selection for the therapy targeting Toll-like receptors (TLR) 7 and 8 follows a recommendation from an independent data monitoring committee after a prespecified analysis of unblinded data. The committee recommended that TeLuRide-006 continue as planned in all other respects.

"EIK1001's activation of both myeloid and plasmacytoid dendritic cells to stimulate both innate and adaptive immunity, bringing a broader repertoire of immune cells to target tumor cells, represents both an orthogonal mechanism and an agent with monotherapy activity. These criteria merit study in combination with checkpoint inhibitors. The selection of an optimized dose for this trial advances our efforts to bring this approach to patients in urgent need of better therapies,” Roy Baynes, MD, PhD, chief medical officer of Eikon, stated in a news release.

Mechanism and Study Design

EIK1001 is an investigational, systemically administered dual agonist of TLR 7 and 8, designed to stimulate both innate and adaptive immune responses against malignancy. According to the company, single-agent activity was observed with EIK1001 in patients with advanced solid tumors in phase 1 trials, and its mechanism is intended to complement the antitumor immune response generated by PD-(L)1 blockade by engaging both myeloid and plasmacytoid dendritic cells.

The phase 2/3 trial, which includes dose optimization and expansion parts, has an estimated enrollment of 740 patients who will be randomly assigned to receive pembrolizumab and EIK1001 or placebo as first-line therapy for advanced melanoma. Patients can have received prior adjuvant or neoadjuvant therapies if all adverse events have stabilized or returned to baseline, with a minimum of 6 months from the last dose of therapy and documented disease progression. Patients could not have active central nervous system metastases.

The primary end points are progression-free survival (PFS) by blinded independent central review and overall survival, with the dose optimization part evaluating overall response rate and adverse events. Secondary end points include duration of response, objective response rate, and investigator-assessed PFS.

Disease Background

Advanced cutaneous melanoma, characterized by spread beyond the primary lesion to regional lymph nodes or distant organs, has variable treatment response; despite the availability of immunotherapy and targeted therapies, responses remain heterogeneous and patients often develop resistance. Baynes noted that combination regimens have yet demonstrated a statistically significant overall survival improvement over checkpoint inhibitor monotherapy in this setting.

REFERENCES

1. Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma. News release. Eikon Therapeutics, Inc. GLOBE NEWSWIRE. August 11, 2026. Accessed August 11, 2026. https://tinyurl.com/pxk3zbz8

2. Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. ClinicalTrials.gov. Updated May 8, 2026. Accessed August 11, 2026. https://clinicaltrials.gov/study/NCT06697301